Viral Protein Patents (Class 536/23.72)
-
Publication number: 20130109742Abstract: This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.Type: ApplicationFiled: January 12, 2011Publication date: May 2, 2013Inventors: Curtis Hewitt, Richard Jude Samulski
-
Publication number: 20130101618Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: April 15, 2011Publication date: April 25, 2013Applicants: OKAIROS AG, TheGovernmentof the UnitedStatesof America asRepre -sentedby theSecretaryoftheDept.ofHealth&HumanSerInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 8426574Abstract: Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus.Type: GrantFiled: May 28, 2010Date of Patent: April 23, 2013Assignees: Washington University, The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: David Wang, Herbert Whiting Virgin, IV, Guoyan Zhao, Stacy Finkbeiner, Jan Vinje, Yan Li, Suxiang Tong
-
Patent number: 8426575Abstract: E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation.Type: GrantFiled: September 21, 2011Date of Patent: April 23, 2013Assignee: The United States of America, as Represented by the Secretary of AgricultureInventors: Manuel V. Borca, Guillermo R. Risatti
-
Patent number: 8426188Abstract: The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions.Type: GrantFiled: July 23, 2010Date of Patent: April 23, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Scott C. Weaver, Ilya V. Frolov, Elena Frolova
-
Patent number: 8420389Abstract: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.Type: GrantFiled: July 20, 2010Date of Patent: April 16, 2013Assignee: Merial LimitedInventor: Jean Christophe Francis Audonnet
-
Publication number: 20130089558Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.Type: ApplicationFiled: June 2, 2009Publication date: April 11, 2013Inventors: Frédéric Tangy, PHILIPPE DESPRES, CHANTAL COMBREDET, MARIE PASCALE FRENKIEL
-
Publication number: 20130089567Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: ApplicationFiled: December 3, 2012Publication date: April 11, 2013Applicant: The USA, as represented by the Secretary, Dept. of Health & Human ServicesInventor: The USA, as represented by the Secretary, Dept.
-
Publication number: 20130089569Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.Type: ApplicationFiled: September 21, 2012Publication date: April 11, 2013Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventor: Helmholtz Zentrum München Deutsches
-
Patent number: 8415463Abstract: Nucleic acid comprising or encoding an RNA replica comprising, in this order, the following segments (i) to (iii): i) a nucleic acid sequence encoding a potexvirus RNA-dependent RNA polymerase or a function-conservative variant thereof; ii) a nucleic acid sequence comprising: a) a potexvirus triple gene block or a function-conservative variant thereof and b) a sequence encoding a potexviral coat protein or a function-conservative variant thereof; or a sequence encoding a tobago viral movement protein; and iii) a heterologous nucleic acid sequence expressible from said replica in a plant or in plant tissue.Type: GrantFiled: September 6, 2007Date of Patent: April 9, 2013Assignee: Icon Genetics GmbHInventors: Sylvestre Marillonnet, Carola Engler, Victor Klimyuk, Yuri Gleba
-
Publication number: 20130078277Abstract: An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein precursor comprises at least substitution of glutamine at position 862 with arginine, as determined with reference to the amino acid sequence as shown in SEQ ID NO: 2 in the Sequence Listing.Type: ApplicationFiled: March 25, 2011Publication date: March 28, 2013Applicants: THE UNIVERSITY OF TOKYO, NIHON UNIVERSITY, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, TORAY INDUSTRIES, INC., JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Yoshihiro Kitamura, Yoko Shimizu, Chie Aoki, Lijuan Yu, Takaji Wakita
-
Publication number: 20130078281Abstract: The present invention includes IFNS activating agents that activate expression of IFN-?, activate NF-?B expression, activate an innate immune response, activate the expression of one or more cytokines, and/or induce the expression of interferon beta (IFN-?) through a RNase L and/or MDA5-dependent pathway. Such IFNS activating agents include single stranded RNAs that encode for conserved region II of the L protein of a negative stranded RNA virus, including, but not limited to, viruses of the family Paramyxoviridae. Also included are methods of making and using such IFNS activating agents and compositions and kits including such IFNS activating agents.Type: ApplicationFiled: November 27, 2012Publication date: March 28, 2013Applicant: University of Georgia Research Foundation, Inc.Inventor: University of Georgia Research Foundation, Inc.
-
Publication number: 20130071833Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.Type: ApplicationFiled: January 18, 2011Publication date: March 21, 2013Applicant: Universiteit Utrecht Holding B.V.Inventors: Petrus Josephus Marie Rottier, Hui-Wen Chang, Herman F. Egberink
-
Publication number: 20130071419Abstract: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.Type: ApplicationFiled: May 23, 2011Publication date: March 21, 2013Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Nikolaos Vasilakis
-
Publication number: 20130071421Abstract: Isolated a Turkey Viral Hepatitis picomavirus-like viruses associated with Turkey viral hepatitis, and isolated nucleic acid sequences and polypeptides are disclosed. Antibodies against antigens from Turkey Viral Hepatitis picornavirus-like viruses, iRNAs which target nucleic acid sequences of the Turkey Viral Hepatitis picornavirus-like virus, methods for detecting the presence or absence of Turkey Viral Hepatitis picomavirus-like viruses in an animal, and immunogenic compositions for inducing an immune response against Turkey Viral Hepatitis picomavirus-like viruses in an animal are also disclosed.Type: ApplicationFiled: October 4, 2010Publication date: March 21, 2013Inventors: W. Ian Lipkin, Thomas Briese, Kirsi Honkavuori, H.L. Shivaprasad
-
Publication number: 20130064844Abstract: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.Type: ApplicationFiled: August 22, 2012Publication date: March 14, 2013Applicant: MedImmune, LLCInventors: Richard Spaete, Winthrop Jackman
-
Publication number: 20130058968Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.Type: ApplicationFiled: October 4, 2010Publication date: March 7, 2013Inventors: W. Ian Lipkin, Gustavo Palacios, Ruth Toril Kongtorp, Edgar Brun
-
Publication number: 20130058897Abstract: Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.Type: ApplicationFiled: April 14, 2010Publication date: March 7, 2013Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Kyuhyun Lee, Seongtae Yun, Daekyung Koh, Hong-Kyu Lee, Eui-Cheol Jo
-
Publication number: 20130059732Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.Type: ApplicationFiled: August 24, 2012Publication date: March 7, 2013Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Leszek Lisowski, Mark A. Kay
-
Patent number: 8389804Abstract: Disclosed herein are viral vectors suitable for transfection into woody trees for purposes of delivering and expressing beneficial genes. Specifically exemplified herein are vectors for transfecting citrus trees. The vectors allow for the expression of useful proteins, such as those that can protect the tree from disease. Specifically exemplified herein are methods of transfecting woody trees that allow multiple applications of vectors while avoiding superinfection exclusion.Type: GrantFiled: August 11, 2011Date of Patent: March 5, 2013Assignee: University of Florida Research Foundation, Inc.Inventors: William O. Dawson, Svetlana Y. Folimonova
-
Patent number: 8389706Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 18 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.Type: GrantFiled: January 21, 2010Date of Patent: March 5, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: David B Weiner, Jian Yan
-
Publication number: 20130052222Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided.Type: ApplicationFiled: October 26, 2012Publication date: February 28, 2013Applicant: The Trustees of the University of PennsylvaniaInventor: The Trustees of the University of Pennsylvania
-
Publication number: 20130052716Abstract: The present inventors developed hepatitis C virus recombinants expressing NS5A from genotype 1a, 1b, 2a, 3a, 4a, 5a, 6a or 7a in the context of a genotype 2a backbone. Additional recombinants express NS5A and the structural proteins (Core, E1 and E2), p7 and NS2 from genotype 1a, 1b, 3a, 4a, 5a, 6a or 7a in the genotype 2a backbone. Sequence analysis of the recombinants recovered after viral passage in Huh7.5 cells revealed adaptive mutations in NS5A and/or NS3. The importance of these mutations for improved growth kinetics was shown in reverse genetic studies.Type: ApplicationFiled: October 1, 2010Publication date: February 28, 2013Applicants: Københavns Universitet, Hvidovre HospitalInventors: Troels Kasper Hoyer Scheel, Judith M. Gottwein, Tanja Bertelsen Jensen, Jens Bukh
-
Publication number: 20130052633Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: ApplicationFiled: July 5, 2012Publication date: February 28, 2013Applicant: Gilead Sciences, Inc.Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
-
Publication number: 20130052226Abstract: The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.Type: ApplicationFiled: February 9, 2011Publication date: February 28, 2013Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Ning Zhi, Neal S. Young, Sachiko Kajigaya
-
Publication number: 20130052634Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: ApplicationFiled: July 5, 2012Publication date: February 28, 2013Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
-
Publication number: 20130045186Abstract: Adeno-associated virus rh.10 sequences, vectors containing same, and methods of use are provided.Type: ApplicationFiled: October 3, 2012Publication date: February 21, 2013Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventor: The Trustees of the University of Pennsylvania
-
Patent number: 8377866Abstract: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.Type: GrantFiled: February 12, 2009Date of Patent: February 19, 2013Assignee: Intron Biotechnology, Inc.Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
-
Publication number: 20130039946Abstract: Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Ems in addition to the inactivation of the (hypothesized) immunomodulating activity residing in Npro. Methods for attenuating pestiviruses such as BVDV, nucleic acids encoding the pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV, of the invention.Type: ApplicationFiled: October 18, 2012Publication date: February 14, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Boehringer Ingelheim Vetmedica Gmbh
-
Patent number: 8372964Abstract: The present invention relates to a plant-infectious nucleic acid molecule from Pepper mottle virus, and a viral vector, a transformed cell and a transgenic plant having it. The present invention first achieves the cloning of the infectious full-length pepper mottle virus cDNA from virus-infected pepper, which enables to perform the molecular biological studies to the infectivity of pepper mottle virus in pepper and tobacco and to provide a plant virus-based vector to highly express a useful foreign protein.Type: GrantFiled: September 26, 2008Date of Patent: February 12, 2013Assignee: Seoul Women's University Industry—University Cooperation FoundationInventors: Ki Hyun Ryu, Mi Yeon Lee, Jin Sung Hong
-
Patent number: 8372963Abstract: The present invention relates to a nucleic acid molecule, which codes for the F-protein of the respiratory syncytial virus (RSV) or a fragment thereof, for the expression in a human cell environment of codon optimized variants of said nucleic acid molecule, vectors and compositions comprising said nucleic acid molecules and the use thereof as vaccines and polypeptides coded by the nucleic acid molecules and method for the production thereof.Type: GrantFiled: December 18, 2007Date of Patent: February 12, 2013Assignees: Pevion Biotech AG, Ruhr-Universitaet BochumInventors: Thomas Grunwald, Klaus Ueberla
-
Publication number: 20130034576Abstract: Provided is a Titi Monkey Adenovirus (TMAdV) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-TMAdV antibodies, vaccines, compositions, methods of detecting TMAdV, methods for assaying for anti-TMAdV compounds, and methods for treating or preventing a TMAdV infection.Type: ApplicationFiled: May 10, 2012Publication date: February 7, 2013Applicant: The Regents of the University of CaliforniaInventors: Charles CHIU, Eunice Chen, Karen Lisa Bales, Jacquelyn Dieter
-
Publication number: 20130028931Abstract: The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus.Type: ApplicationFiled: July 26, 2012Publication date: January 31, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Andreas GALLEI
-
Publication number: 20130029379Abstract: The present invention provides viral vector compositions of high titre and purity, as well as methods for production of said compositions. The methods of the invention incorporate multiple features, such as production of viral vector particles in serum free media and multiple harvesting steps following transduction of the producer cell which provides for enhanced production of said viral vectors. The viral vector compositions of the invention, by virtue of their high titre and purity, minimize the deleterious phenotypic changes that typically occur following transduction of target cells, such as loss of a sub-populations of transduced cells, and effects on proliferation, differentiation, reprogramming or functionality of transduced cells.Type: ApplicationFiled: July 26, 2012Publication date: January 31, 2013Applicant: VECTALYS SASInventors: Pascale Bouillé, Hélène Vergnault, Régis Gayon, Yohann Moal
-
Patent number: 8361708Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.Type: GrantFiled: February 10, 2010Date of Patent: January 29, 2013Assignee: Versitech LimitedInventors: Joseph S. M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Publication number: 20130023030Abstract: Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.Type: ApplicationFiled: September 27, 2007Publication date: January 24, 2013Applicant: The Government of the U.S.A, Represented by the Sectretary, Dept. of Health and Human ServicesInventors: Mario H. SKIADOPOULOS, Brian R. Murphy, Peter L. Collins
-
Publication number: 20130023034Abstract: The invention relates to a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein, wherein a nuclear localization signal (NLS) in said Parvoviral Rep protein is mutated as compared with a corresponding wild type sequence. The invention also relates to a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein, wherein the zinc finger domain in said Parvoviral Rep protein is mutated as compared with a corresponding wild type sequence. Further, the invention relates to a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein, wherein an amino acid at position 43, 57, 79, 97, 120, 179, 305, 484, 493 or 571 of the said Parvoviral Rep protein is mutated in comparison to a corresponding wild type sequence, said amino acid position being defined with reference to SEQ ID NO: 2.Type: ApplicationFiled: March 11, 2011Publication date: January 24, 2013Inventors: Yvet Noordman, Jacek Lubelski, Andrew Christian Bakker
-
Patent number: 8357792Abstract: A polynucleotide base sequence represented by SEQ ID NO: 22, a vector containing the polynucleotide and a method of preparing a small round structure virus (SRSV) virus-like particle in insect cells with vector.Type: GrantFiled: October 6, 2011Date of Patent: January 22, 2013Assignees: Japan as represented by Director-General National Institute of Infectious Diseases, Denka Seiken Co., Ltd.Inventors: Naokazu Takeda, Katsuro Natori, Tatsuo Miyamura, Kunio Kamata, Toshinori Sato, Seiya Sato
-
Publication number: 20130017217Abstract: The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens, which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of any of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods of inducing an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.Type: ApplicationFiled: June 18, 2012Publication date: January 17, 2013Applicant: Vical IncorporatedInventors: Gary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
-
Publication number: 20130017253Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Inventors: Alessandro SETTE, John Sidney, Scott Southwood, Robert Chestnut, Esteban Celis, Howard M. Grey
-
Publication number: 20130017572Abstract: Synthetic DNA molecules encoding various HPV proteins are provided. The codons of the synthetic molecules are designed so as to use the codons that preferentially increase expression of the polypeptide in the host cell, which in preferred embodiments is a human cell. The codons are modified in order to minimize, decrease or eliminate cellular destruction of the polypeptide construct.Type: ApplicationFiled: April 30, 2010Publication date: January 17, 2013Inventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento
-
Patent number: 8354113Abstract: According to the present invention, there is provided a means of expressing and displaying a protein on the cell surface of a bifidobacterium. In the gene for expressing a protein on the surface of a bifidobacterium of the present invention, a gene coding for a bifidobacterium-derived GNB/LNB substrate-binding membrane protein and a gene coding for the target protein or peptide are linked in this order from the 5? end side. Thus, a bifidobacterium transformed by introducing the gene for expressing a protein on the surface of a bifidobacterium of the present invention expresses the target protein or peptide on the surface thereof. When the target protein or peptide is an antigen protein or an antigen peptide, the transformed bifidobacterium of the present invention is useful as an oral vaccine.Type: GrantFiled: September 17, 2010Date of Patent: January 15, 2013Assignee: Morishita Jintan Co., Ltd.Inventors: Toshiro Shirakawa, Sakura Yamamoto, Takane Katayama, Jun Wada, Yasunobu Kano, Masanori Asada, Kosuke Shimamoto
-
Patent number: 8354115Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.Type: GrantFiled: April 4, 2008Date of Patent: January 15, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Ralph A. Tripp, Larry J. Anderson, Michael P. Brown
-
Patent number: 8354518Abstract: The present invention features methods for enhancing the ability of a genotype 2b NS5B sequence to function in a replicon, for producing replicons containing a functional genotype 2b NS5B, and for using replicons to measure the ability of a compound to affect HCV replication that is sustained with the genotype 2b polymerase. Also featured is a genotype 1b NS4B adaptive mutation. The ability to produce replicons containing a functional genotype 2b NS5B is illustrated by the production of chimeric replicons based on HCV genotype 1b where substantially all the NS5B sequence is replaced with a genotype 2b NS5B.Type: GrantFiled: November 3, 2004Date of Patent: January 15, 2013Assignees: Merck Sharp & Dohme Corp., Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Steven W. Ludmerer, Donald J. Graham, Robert L. LaFemina, Osvaldo A. Flores, Maura Pizzuti, Cinzia Traboni
-
Publication number: 20130011427Abstract: Flaviviruses represent an increasing global public health issue, with no prophylactic and therapeutic formulations currently available for many of them. The combination of factors such as evolutionary change, global warming and wide range of animal hosts suggest the possible occurrence of Flavivirus strains with greater distribution and human pathogenicity. There is, thus, a need for greater understanding of viral protein sequences that function in the human immune responses. The evolutionary diversity of the reported sequences of major flaviviruses, such as dengue virus, yellow fever virus, Japanese encephalitis virus, and West Nile virus were analyzed with a combination of experimental and bioinformatics methodologies. The analysis of all reported sequences revealed that these species-specific peptide tags are highly conserved and are potential T-cell epitopes due to correspondence to known or predicted epitopes.Type: ApplicationFiled: December 16, 2010Publication date: January 10, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: J. Thomas August, Tin Wee Tan, Asif Mohammad Khan
-
Publication number: 20130011425Abstract: Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: ApplicationFiled: May 14, 2012Publication date: January 10, 2013Applicant: University of WashingtonInventors: David M. Koelle, Zhi Liu, Lawrence Corey
-
Publication number: 20130011435Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: August 6, 2010Publication date: January 10, 2013Applicant: Transgene SAInventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Publication number: 20130004538Abstract: This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.Type: ApplicationFiled: July 9, 2012Publication date: January 3, 2013Inventors: Lee A. Bulla, JR., Jeffrey Marcus Clark, Natalya Griko, Jian Sun, Ralph Clark
-
Publication number: 20130004461Abstract: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.Type: ApplicationFiled: May 18, 2012Publication date: January 3, 2013Applicant: THE TRUSTEES OF THE UNIVERSITY OF PANNSYLVANIAInventors: SOUMITRA ROY, JAMES M. WILSON
-
Publication number: 20130004529Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.Type: ApplicationFiled: April 27, 2012Publication date: January 3, 2013Inventors: David B. Weiner, Jian Yan, Dominick Laddy